Innovent Biologics (01801) Report Interpretation

Overview

Goldman Sachs argues that Innovent’s stronger-than-expected second-quarter product sales demonstrate an accelerating and increasingly diversified commercial franchise. It expects the market’s focus to shift from the visibility of 2027 revenue growth toward margins and bottom-line execution as the company scales.

Core views

Innovent reported 1H26 product revenue of more than Rmb8.2bn, up 55% year on year. Second-quarter product revenue exceeded Rmb4.3bn, growing about 60% year on year versus about 50% in 1Q26 and ahead of Goldman Sachs’ Rmb4.1bn estimate. The institution views this as evidence that commercial momentum continued to accelerate and as supportive of its expectation that Innovent can progress toward its Rmb20bn product-sales goal for 2027. Its product-sales estimates are Rmb17.7bn for FY26 and Rmb23.1bn for FY27. The report emphasizes that growth is becoming less dependent on Tyvyt. Tyvyt sales were US$130mn, down 5% year on year, or about Rmb836mn according to Eli Lilly’s report. In contrast, Goldman Sachs identifies broader penetration of five newly NRDL-included oncology products—particularly lung-cancer therapies addressing RET, KRAS G12C, ROS1 and EGFR—as well as the expansion of the general-biomedicine franchise. The latter is led by mazdutide, tafolecimab and teprotumumab. Mazdutide is estimated to have generated more than Rmb700mn in 2Q26, about 16% of product sales. Goldman Sachs continues to view 2026 as an important additional window for mazdutide, with a Rmb4bn–5bn sales target in 2027, because generic approval in China has been postponed. As Innovent’s commercial scale rises, Goldman Sachs expects investor discussion to move increasingly toward profitability. It estimates innovative-drug sales of Rmb8.5bn in FY25 and Rmb14bn in FY26, approaching the scale of major China pharmaceutical peers cited in the report: Hengrui at Rmb16bn/Rmb21bn and Hansoh at Rmb10bn/Rmb12bn for FY25/FY26. Management has stated a goal to raise net profit margin to the high-teens to mid-20% range, excluding business-development income, by 2030. Near-term profitability debate is expected to center on biosimilar volume-based procurement, the trajectory of selling expenses, ex-China R&D investment and business-development income. Goldman Sachs revised 2026E–2028E EPS to Rmb1.38/Rmb3.17/Rmb4.30 from Rmb2.09/Rmb3.34/Rmb4.35. The revisions reflect the strong 2Q26 sales, updated FY26 sales assumptions that include potential year-end channel rebates for NRDL products such as mazdutide, IL-23p19 and CTLA-4, and higher expected SG&A spending. Despite lower EPS estimates, the institution raised its 12-month DCF-based target price to HK$111.68 from HK$107.04. The valuation uses a 10% discount rate and 3% terminal growth rate. Goldman Sachs considers the shares undervalued because the market-implied 12% WACC is seen as valuing only de-risked indications and not fully recognizing revenue growth or pipeline value; it retains a Buy rating.

Analysis framework

Goldman Sachs first assesses the sales result against its estimates and the prior quarter, then examines which products are driving growth and whether the commercial base is diversifying. It compares Innovent’s innovative-drug scale with major China pharmaceutical peers, identifies the margin variables likely to matter next, updates earnings assumptions, and applies a risk-adjusted DCF valuation to derive its 12-month target price.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Risk-adjusted discounted cash flow valuation

  The report derives its 12-month target price by discounting projected cash flows using a 10% discount rate and a 3% terminal growth rate.

• Industry AnalysisVolume-price decomposition

  Product-level sales and commercial-mix analysis

  The report explains sales momentum through the relative contribution of Tyvyt, newly reimbursed oncology products and the general-biomedicine franchise, including mazdutide’s estimated sales contribution.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Innovent Biologics (01801.HK)

  Primary covered company; the report links its valuation case to accelerating diversified product sales, pipeline depth and commercialization execution.

  Strengths

  Product-sales acceleration, broader drivers beyond Tyvyt, mazdutide ramp-up, a 30+-asset pipeline, commercialization capability and collaboration with Eli Lilly.

  Weaknesses

  Near-term earnings estimates were reduced partly for higher expected SG&A spending and potential NRDL channel rebates.

  Comparison

  Innovative-drug sales scale is moving toward that of Hengrui and Hansoh, according to Goldman Sachs estimates.

  Risks

  PD-1/L1 competition, uncertain approvals, safety-related restrictions on off-label use and R&D project failure.

Key data

• 1H26 product revenueOver Rmb8.2bn+55% year on year.
• 2Q26 product revenueOver Rmb4.3bnAbout +60% year on year, versus +50% in 1Q26 and Goldman Sachs estimate of Rmb4.1bn.
• Mazdutide 2Q26 sales estimateOver Rmb700mnAbout 16% of product sales.
• FY26/FY27 product-sales estimatesRmb17.7bn / Rmb23.1bnGoldman Sachs estimates; the company’s 2027 product-sales goal is Rmb20bn.
• 2026E–2028E EPSRmb1.38 / Rmb3.17 / Rmb4.30Revised from Rmb2.09 / Rmb3.34 / Rmb4.35.
• 12-month target priceHK$111.68Raised from HK$107.04; based on a 10% discount rate and 3% terminal growth rate.

Impact & implications

The report views the sales result as reinforcing Innovent’s transition to a broader commercial platform and reducing debate over its 2027 sales ambition. It expects attention to turn toward margin delivery, with reimbursement-related rebates, selling costs, overseas R&D spending and business-development income determining the pace of bottom-line improvement.

Risks

• Competition in China’s PD-1/L1 market could intensify.
• Approval timing for key candidates is uncertain.
• Safety issues could lead to restrictions on off-label use.
• R&D projects could fail.

What to watch

• Whether Innovent sustains progress toward its Rmb20bn 2027 product-sales goal.
• Mazdutide’s ramp-up and the effect of postponed generic approval in China.
• Biosimilar volume-based procurement, selling-expense trends, ex-China R&D investment and business-development income as drivers of profitability.
• Potential year-end channel rebates for NRDL products including mazdutide, IL-23p19 and CTLA-4.